Cadrenal Therapeutics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Cadrenal Therapeutics is a development-stage biopharmaceutical company developing tecarfarin, an oral, reversible anticoagulant for patients with rare cardiovascular conditions requiring chronic anticoagulation. Tecarfarin has FDA orphan drug and Fast Track designations for certain ESKD and atrial fibrillation indications and received an additional orphan drug designation for patients with implanted mechanical circulatory support devices in April 2024. The filing covers the three months ended March 31, 2024; financial statements are unaudited.
Financial Performance and Position
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | No revenue reported | No revenue reported | Pre-revenue |
| General and administrative expense | $1.126 million | $0.965 million | Up 17% |
| Research and development expense | $0.629 million | $3.235 million | Down 81% |
| Total operating expenses | $1.756 million | $4.200 million | Down 58% |
| Interest and dividend income | $0.092 million | None reported | New income source |
| Net loss | $1.663 million | $5.174 million | Loss reduced 68% |
| Basic and diluted loss per share | $0.10 loss | $0.48 loss | Improved |
| Cash used in operating activities | $1.836 million | $1.413 million | Use increased 30% |
The company reported no revenue and remains unprofitable, so a revenue-based profit margin is not meaningful. Operating expenses represented the company’s operating loss because there was no revenue. Q1 2024 research and development expense benefited primarily from the absence of the $3.0 million stock issuance for acquired in-process research and development recorded in Q1 2023.
- Cash and cash equivalents were $6.566 million at March 31, 2024, compared with $8.403 million at December 31, 2023.
- Working capital was $6.172 million and accumulated deficit was $16.735 million at March 31, 2024.
- Total liabilities were $0.856 million, consisting primarily of accounts payable, accrued liabilities, and operating lease liabilities. Management reported no debt.
- Total assets were $7.048 million and stockholders’ equity was $6.192 million at March 31, 2024.
- Cash used in operations was $1.836 million; financing activities provided only $298 from pre-funded warrant exercises.
- Interest and dividend income of $92,327 was earned on money market fund investments.
Material Changes Versus the Prior Comparable Period
- Net loss declined by $3.510 million, primarily because Q1 2023 included a $3.0 million non-cash research and development charge related to shares issued for an asset purchase, a $0.740 million loss on debt extinguishment, and a $0.216 million derivative-liability fair-value charge.
- General and administrative expense increased $161,261, or 17%, due mainly to higher personnel costs following the addition of a Chief Operating Officer, increased public-company expenses, and higher consulting fees. These increases were partly offset by lower stock-based compensation.
- Research and development expense decreased $2.606 million, or 81%, from the prior period, but personnel, consulting, and chemistry, manufacturing and controls costs increased.
- Cash used in operations increased despite the lower net loss, reflecting changes in prepaid expenses, deferred offering costs, accrued liabilities, and accounts payable.
- The company issued 2,985,715 common shares upon exercise of all outstanding pre-funded warrants, increasing shares outstanding from 13,022,754 at December 31, 2023 to 16,008,469 at March 31, 2024.
- Outstanding warrants totaled 4,674,786 at March 31, 2024, and outstanding stock options totaled 2,195,000, creating potential future dilution.
Guidance, Outlook, Risks, and Unusual Items
- Management stated that approximately $6.1 million of cash as of May 9, 2024 was expected to fund operations for at least the next twelve months from the filing date.
- Additional funding is required to complete the planned Phase 3 clinical trial and submit a New Drug Application. Management intends to seek equity and debt financing and potential partnering transactions.
- There is no assurance that financing or partnering transactions will occur on acceptable terms or at all. Failure to obtain funding could delay or reduce research programs or cause the company to limit or cease operations.
- The company has incurred operating losses and negative operating cash flows since inception and states that its ability to continue as a going concern depends on future financing and business development activities.
- Key risks include clinical-trial execution, regulatory approval, manufacturing capability, competition, market adoption, and the need for substantial additional capital.
- The filing reports no material legal proceedings, no material changes to previously disclosed risk factors, and no off-balance-sheet arrangements.
- Management evaluated disclosure controls as effective as of March 31, 2024, with no material changes in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Timing, design, cost, and financing plan for the planned Phase 3 trial and NDA submission.
- Remaining cash runway relative to the stated requirement for additional funding.
- Potential dilution from 4,674,786 outstanding warrants and 2,195,000 stock options.
- Clinical and regulatory status of tecarfarin, including the implications of its orphan drug and Fast Track designations.
- Quarterly operating cash burn and whether research and development spending will increase as the Phase 3 program advances.
- Terms and utilization of the March 2024 at-the-market offering agreement and any subsequent equity or debt financing.